IPAF1C

IPAF1C is a inhibitor of the polymerase-associated factor 1 complex (PAF1C) with specific targeting to the PAF1 binding groove of CTR9 (a key subunit of PAF1C) . iPAF1C disrupts PAF1C assembly by interfering with the PAF1-CTR9 interaction. iPAF1C selectively impairs BRD4-mediated recruitment of PAF1 to chromatin at hypoxia-responsive genes and inhibits RNA polymerase II (RNAPII) pause release. iPAF1C increases the population of HIV-1 NL4.3 Nef-IRES-GFP infected primary human CD4+T cells in a dose-dependent manner. PAF1C can be used for the study of infection and diseases associated with abnormal hypoxic adaptation (e.g., cancers, neurological disorders) [1][2].

Product Specifications

CAS Number

[950403-60-8]

UNSPSC

12352005

Target

DNA/RNA Synthesis; HIV

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ipaf1c.html

Purity

99.59

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(C1CCN(CC1)C2=NC3=C(N2CC4=CC(F)=CC=C4)C=CC=C3)NC5=CC=C(C(C)=C5)Br

Molecular Formula

C27H26BrFN4O

Molecular Weight

521.42

References & Citations

[1]Shimaa H A Soliman, et al. Enhancing HIV-1 latency reversal through regulating the elongating RNA Pol II pause-release by a small-molecule disruptor of PAF1C. Sci Adv. 2023 Mar 10;9 (10) :eadf2468.|[2]Soliman SHA, et al. Transcriptional elongation control of hypoxic response. Proc Natl Acad Sci U S A. 2024 Apr 9;121 (15) :e2321502121.